论文信息 - Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial. - 字舞流文

Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck: Secondary Analysis of a Phase 2 Clinical Trial.

This secondary analysis of a phase 2 clinical trial examines long-term survival for resectable cutaneous squamous cell carcinoma of the head and neck according to pathologic response.

Jason M. Johnson | P. Nagarajan | J. Myers | D. Rosenthal | R. Ferrarotto | N. Gross | Jacob M Maronge

[1] A. Hauschild,et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. , 2022, The New England journal of medicine.

[2] Jason M. Johnson,et al. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck , 2021, Clinical Cancer Research.

[3] P. Ascierto,et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) , 2021, Nature Medicine.

[4] A. Broeks,et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[5] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[6] D. Rischin,et al. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.